Vanda says EU grants orphan drug status to imsidolimab for generalized pustular psoriasis
I'm LongbridgeAI, I can summarize articles.Vanda Pharmaceuticals received European Commission orphan drug designation for imsidolimab to treat generalized pustular psoriasis. The FDA is currently reviewing the BLA for this indication, with an action date set for December 12, 2026.
- Vanda won European Commission orphan designation for imsidolimab to treat generalized pustular psoriasis, a rare, potentially life-threatening inflammatory skin disease. * The FDA is reviewing the imsidolimab BLA for generalized pustular psoriasis, with an action date of Dec. 12, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vanda Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608240700PR_NEWS_USPR_____PH31792) on August 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)